用于地中海贫血的铁螯合剂。 - Suppr

Iron chelators for thalassaemia.

作者信息

Hershko C, Konijn A M, Link G

机构信息

Department of Medicine, Shaare Zedek Medical Centre, Jerusalem, Israel.

出版信息

Br J Haematol. 1998 Jun;101(3):399-406. doi: 10.1046/j.1365-2141.1998.00726.x.

DOI:10.1046/j.1365-2141.1998.00726.x

PMID:9633877

Abstract

摘要

相似文献

Iron chelators for thalassaemia.

Br J Haematol. 1998 Jun;101(3):399-406. doi: 10.1046/j.1365-2141.1998.00726.x.

Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.

Haematologica. 2006 Jun;91(6 Suppl):ELT04.

Pharmacotherapy of iron overload in thalassaemic patients.

Expert Opin Pharmacother. 2003 Oct;4(10):1763-74. doi: 10.1517/14656566.4.10.1763.

Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.

Curr Med Chem. 2005;12(23):2663-81. doi: 10.2174/092986705774463003.

Iron chelation with oral deferiprone in patients with thalassemia.

N Engl J Med. 1998 Dec 3;339(23):1713-4. doi: 10.1056/nejm199812033392320.

The effectiveness of deferiprone in thalassemia.

Blood. 1997 Jul 15;90(2):894.

New chelation therapies and emerging chelating drugs for the treatment of iron overload.

Expert Opin Emerg Drugs. 2006 Mar;11(1):1-5. doi: 10.1517/14728214.11.1.1.

Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.

Hemoglobin. 2008;32(1-2):17-28. doi: 10.1080/03630260701726491.

Iron mobilization using chelation and phlebotomy.

J Trace Elem Med Biol. 2012 Jun;26(2-3):127-30. doi: 10.1016/j.jtemb.2012.03.009. Epub 2012 May 5.

Deferiprone for thalassaemia.

Lancet. 2000 Jul 29;356(9227):428-9. doi: 10.1016/s0140-6736(05)73574-1.

引用本文的文献

Salvage Structures, Known as Iron Chelating Agents, Acquired from the Nature and Matured in the Labs.

Curr Med Chem. 2025;32(21):4225-4258. doi: 10.2174/0109298673264118231228042816.

Application of Fuzzy AHP for Medication Decision Making in Iron-Chelating Medications for Thalassemia.

Pharmacy (Basel). 2025 Jun 15;13(3):86. doi: 10.3390/pharmacy13030086.

Role of Metal Cations of Copper, Iron, and Aluminum and Multifunctional Ligands in Alzheimer's Disease: Experimental and Computational Insights.

ACS Omega. 2023 Jan 25;8(5):4508-4526. doi: 10.1021/acsomega.2c06939. eCollection 2023 Feb 7.

Iron overload in Beta thalassaemia major and intermedia patients.

Maedica (Bucur). 2013 Sep;8(4):328-32.

Deferiprone: structural and functional modulating agent of hemoglobin fructation.

Mol Biol Rep. 2014 Mar;41(3):1723-9. doi: 10.1007/s11033-014-3021-0. Epub 2014 Jan 11.

Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.

Cochrane Database Syst Rev. 2013 Aug 21;2013(8):CD004450. doi: 10.1002/14651858.CD004450.pub3.

Ineffective erythropoiesis in β -thalassemia.

ScientificWorldJournal. 2013 Mar 28;2013:394295. doi: 10.1155/2013/394295. Print 2013.

Fibroblast involvement in soft connective tissue calcification.

Front Genet. 2013 Mar 5;4:22. doi: 10.3389/fgene.2013.00022. eCollection 2013.

Synthesis and biological evaluation of bidentate 3-hydroxypyridin-4-ones iron chelating agents.

Res Pharm Sci. 2011 Jul;6(2):117-22.

A mouse model of β-thalassemia shows a liver-specific down-regulation of Abcc6 expression.

Am J Pathol. 2011 Feb;178(2):774-83. doi: 10.1016/j.ajpath.2010.10.004.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Iron chelators for thalassaemia.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献